Oral Answers to Questions

Emma Foody Excerpts

Thursday 29th January 2026 Commons Chamber

[Chris Bryant]

We have been working hard to secure good outcomes for many businesses in the hon. Gentleman’s constituency. Walker’s Shortbread is doing a phenomenal job of exporting around the world. I know that because I have seen them in supermarkets in Auckland, Melbourne, Dubai and all over the place. Similarly, we are trying to get a good deal with the United States on whisky. We already have a good deal with India on whisky, and the Prime Minister and others will be talking about whisky in China over the next few days. I do wish the hon. Gentleman would be a bit cheerier. He has one of the most beautiful constituencies in the land. Whether it is the Lairig Ghru, the Rothiemurchus estate, the ospreys in Loch Garten, or Loch an Eilein, it is absolutely beautiful. He could just be a bit cheerier!

[Emma Foody (Cramlington and Killingworth) (Lab/Co-op)]

T5. The north-east has one of the largest pharmaceutical clusters, identified in the north-east growth plan as a key growth sector. My constituency has some of the leading companies, such as Organon and Sterling Pharma, who are providing good-quality jobs and exporting around the world. How are the Government backing our pharmaceutical sector, and supporting the north-east to secure and expand opportunities in this area?

[The Parliamentary Under-Secretary of State for Business and Trade (Chris McDonald)]

I thank my hon. Friend for the work she is doing to highlight the north-east’s role as a key part of our life sciences and pharmaceutical industries. She mentions Organon in her constituency. Its Cramlington site was singled out by the leadership of that business at the J. P. Morgan healthcare conference in San Francisco recently. In two weeks’ time, I will be opening Fujifilm’s biotechnology factory in Billingham in my own constituency—a £400 million investment in north-east biosciences. Our life sciences sector plan is backing the pharmaceutical manufacturing industry with £2 billion of investment and our UK-US deal is delivering zero-tariff access for UK pharmaceutical exports.